GLP-1 Weight Loss Medications — What They Do, How They Work, and Why Hormones Change Everything

GLP-1 receptor agonists — including semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound) — are injectable medications that mimic a hormone your body naturally produces called GLP-1 (glucagon-like peptide-1). This hormone is released by your gut after eating and plays a central role in appetite regulation, blood sugar management, and how your body processes fuel.

When you take a GLP-1 medication, it amplifies these natural signals. It slows gastric emptying — meaning food stays in your stomach longer, so you feel full sooner and stay full longer. It acts on appetite centers in the brain, reducing the constant hunger and food noise that many women describe as one of the most exhausting parts of perimenopause weight gain. And it improves insulin sensitivity, helping your cells respond to insulin more efficiently — which directly addresses the insulin resistance that builds during the hormonal transition.

Tirzepatide goes a step further. It's a dual agonist — it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, providing two metabolic pathways of support. Clinical trials have shown tirzepatide produces greater average weight loss than semaglutide alone, though individual responses vary significantly.

These medications are administered as a weekly subcutaneous injection — a small needle, once a week. Doses are titrated gradually over several weeks to minimize side effects and find the optimal therapeutic level for your body. This isn't a crash approach. It's a slow, steady recalibration of how your body manages hunger, fullness, and fuel.

Here's what most weight loss clinics don't tell you: GLP-1 medications work inside a metabolic environment — and during perimenopause and menopause, that environment has fundamentally changed. Estrogen decline drives insulin resistance. Progesterone loss elevates cortisol, which promotes fat storage. Testosterone decline reduces muscle mass, which slows basal metabolic rate. Thyroid function can shift, further slowing metabolism.

A GLP-1 medication prescribed without addressing these hormonal shifts is fighting against a current. It can still produce weight loss — the drugs are powerful — but the results may be slower, less dramatic, and harder to maintain than they would be if the hormonal foundation were supported simultaneously.

When you combine GLP-1 therapy with hormonal optimization — restoring estrogen to improve insulin sensitivity, supporting progesterone to normalize cortisol, adding testosterone to preserve muscle mass — the metabolic environment CHANGES. Insulin resistance decreases. Cortisol-driven fat storage slows. Muscle preservation means your metabolism stays higher even as you lose weight. The GLP-1 is no longer fighting upstream — it's working with a body that's metabolically ready to respond.

This is why women who get GLP-1s from a weight loss clinic often see different results than women who get them as part of a comprehensive hormonal and metabolic protocol. Same medication. Different metabolic context. Different outcomes.

Research increasingly supports this combined approach. Estrogen's role in insulin sensitivity is well-established. Testosterone's role in preserving lean mass during weight loss is increasingly documented. The combination of metabolic medication with hormonal support represents a more complete strategy than either alone — particularly for women over 40.

How It Happens

GLP-1 therapy is most appropriate for women who have a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition (insulin resistance, prediabetes, high blood pressure, elevated cholesterol, or sleep apnea). These are the clinical criteria — but the real-world picture is more nuanced.

Many women in perimenopause and menopause have gained 15-40 pounds that won't respond to the strategies that worked in their 30s. They're eating well. They're exercising. Nothing is moving. Their metabolism changed because their hormones changed — and willpower has nothing to do with it. For these women, GLP-1 therapy can break through the metabolic resistance that diet and exercise alone cannot overcome.

GLP-1 medications are NOT appropriate as a standalone cosmetic weight loss tool. They're not appropriate for women who are underweight or normal weight seeking to lose a few vanity pounds. They carry real side effects — primarily gastrointestinal (nausea, constipation, decreased appetite) — and they require medical supervision, lab monitoring, and gradual dose titration.

They're also not a substitute for addressing the root cause. If insulin resistance, cortisol dysregulation, thyroid dysfunction, or hormonal decline are driving the weight gain — and they usually are during perimenopause — the GLP-1 medication should be part of a comprehensive protocol, not the entire protocol. That's the difference between using these medications at a weight loss mill and using them at a practice that understands the full picture.

• •GLP-1 medications require medical supervision and lab monitoring — they are not over-the-counter supplements
• •Rapid weight loss without muscle preservation strategies can worsen metabolic health long-term
• •GLP-1 medications may interact with certain conditions — full medical history review is required before prescribing
• •Side effects (nausea, GI discomfort) are common early but typically improve — dose titration is essential

Treatment begins after comprehensive lab work. We don't prescribe GLP-1 medications based on your weight alone — we evaluate your full metabolic picture: insulin levels, HbA1c, thyroid function, inflammatory markers, and your complete hormonal panel. This data determines whether a GLP-1 is appropriate and which medication (semaglutide or tirzepatide) is the better fit for your specific metabolic profile.

Dosing starts low and increases gradually — typically over 8-12 weeks — to minimize side effects. The most common side effects are gastrointestinal: nausea (especially in the first few weeks), decreased appetite, constipation, and occasional acid reflux. These typically improve as your body adjusts to each dose level. Eating smaller meals, staying hydrated, and following the nutritional guidance we provide significantly reduces discomfort.

Most women begin noticing appetite changes within the first 1-2 weeks. The 'food noise' quiets. Portions naturally decrease. Cravings — especially the nighttime carb cravings driven by insulin resistance — begin to fade. Weight loss typically becomes visible by weeks 4-8, with the most significant changes occurring over months 2-6 as the medication reaches therapeutic doses.

We monitor your progress with follow-up labs at regular intervals. We're watching not just your weight, but your metabolic markers — is insulin sensitivity improving? Is inflammation decreasing? Is your body composition changing (losing fat while preserving muscle)? These markers tell us whether the protocol is working at the level that matters — not just the scale, but the metabolic health underneath it.

For women simultaneously receiving hormonal optimization, the results often compound. Hormonal support improves sleep, reduces cortisol, restores insulin sensitivity, and preserves muscle — which means the GLP-1 is working inside a metabolic environment that's cooperating rather than resisting.

Track these for 2–4 weeks before your appointment

💾 Save this tracker — bring it to your first appointment

At most weight loss clinics, you step on a scale, answer a questionnaire, and get a prescription. At Pause & Reset, we evaluate the metabolic SYSTEM the medication will be working inside — because context determines outcome.

We test 15+ markers before prescribing. We evaluate your hormonal foundation, your thyroid function, your insulin status, your inflammation levels, and your nutrient status. We understand what's DRIVING the weight gain before we add a medication to address it. This means we can identify whether hormonal support, metabolic optimization, or both should accompany the GLP-1 — and design a protocol that addresses every contributing factor, not just the appetite piece.

We select between semaglutide and tirzepatide based on YOUR data — your insulin resistance level, your metabolic profile, your side effect sensitivity, and your goals. This isn't a one-medication-fits-all practice. Some women respond better to one than the other, and the selection should be clinical, not random.

We monitor body COMPOSITION, not just body weight. Losing 30 pounds means something very different if 25 of those pounds were fat versus if 10 were muscle. Preserving muscle during GLP-1 therapy is critical — especially for women over 40 — and it requires protein guidance, strength training recommendations, and often testosterone support. We track this and adjust accordingly.

And we plan for what happens AFTER. GLP-1 therapy isn't necessarily forever. For many women, it's a bridge — a tool that breaks through metabolic resistance while hormonal optimization and lifestyle changes establish a new baseline. We discuss timelines, tapering strategies, and long-term maintenance from the beginning so there are no surprises.